Non-GLP dose-range finding and GLP toxicity studies in minipigs and in vitro drug-drug interaction studies for a small peptide
Active Awarded Last action
- Contract number
- 75N95024F00002
- Awardee
-
Battelle Memorial Institute UEI F125YU6SWK59
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,477,057
Award facts
- Contract value 95% obligated
-
- $2,477,057.00 Current, with exercised options
- $2,611,477.00 Potential, with all options
- Completion date 86% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $327,971 | |
| Exercise an Option | $224,497 | |
| Change Order | $371,666 | |
| Exercise an Option | $973,537 | |
| Other Administrative Action | $0 | |
| Original award | $579,386 |
About this award
This is a federal contract award from the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, to Battelle Memorial Institute. The $2,611,477.00 cost-plus-fixed-fee contract is for non-GLP dose-range finding and GLP toxicity studies in minipigs, as well as in vitro drug-drug interaction studies for a small peptide. The contract was awarded under the Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders indefinite-delivery, indefinite-quantity (IDIQ) vehicle.
The contract has no set-aside designation. Battelle has subcontracted portions of the work to QPS LLC, a minority-owned limited liability company, to conduct non-GLP dose-range finding and GLP toxicity studies, and to Inotiv, Inc., a for-profit contract research organization, to provide study execution services. The contract supports NCATS' mission in advancing translational science and biomedical research to address neurological disorders.
Quick answers
Who was awarded contract 75N95024F00002?
75N95024F00002 was awarded to Battelle Memorial Institute by National Institute on Drug Abuse (National Institutes of Health) on March 26, 2024.
How much is contract 75N95024F00002 worth?
The government has obligated $2,477,057 on 75N95024F00002. Its potential value, with all options, is $2,611,477.
Which agency awarded contract 75N95024F00002?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95024F00002, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95024F00002 an order under another contract?
Yes. 75N95024F00002 is a delivery order under 75N95022D00021, an indefinite delivery contract, on Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders.
Was contract 75N95024F00002 competed?
The extent of competition for 75N95024F00002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award